ADMA Biologics, Inc. (ADMA) Initiated at Buy as Canaccord Cites Improving Revenue and Margin Trends [Yahoo! Finance]
ADMA Biologics Inc (ADMA)
Last adma biologics inc earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.admabiologics.com
Company Research
Source: Yahoo! Finance
TheFly reported on April 21 that Canaccord Genuity initiated coverage of ADMA with a Buy rating and set a price target of $21. The firm highlighted an attractive risk-reward profile at current valuation levels. It noted that recent weakness in the stock has been driven by investor concerns over revenue recognition and the underlying demand trends for the company's primary IVIG therapy, Asceniv. However, management commentary, along with positive feedback from key clinical stakeholders, was viewed as supportive of continued revenue growth and improving profitability trends going forward. Linked to that, on March 27, ADMA Biologics, Inc. (NASDAQ:ADMA) issued a detailed response addressing claims made in a recent short-seller report, stating that the allegations were misleading and not supported by its operational and commercial data. The company emphasized that demand for its immune globulin products, including ASCENIV, continues to grow based on information from distributors and dir
Show less
Read more
Impact Snapshot
Event Time:
ADMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADMA alerts
High impacting ADMA Biologics Inc news events
Weekly update
A roundup of the hottest topics
ADMA
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAACCESS Newswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAACCESS Newswire
- ADMA Legal Notification: ADMA Biologics Securities Class Action Investigation Ongoing – Investors with Losses after 29% Stock Drop Notified to Contact BFA LawGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADMA Biologics, Inc. - ADMAACCESS Newswire
- ROSEN, SKILLED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Inquire About Securities Class Action Investigation - ADMAACCESS Newswire
ADMA
Earnings
- 11/5/25 - Miss
ADMA
Sec Filings
- 4/15/26 - Form ARS
- 4/15/26 - Form DEFA14A
- 4/15/26 - Form DEF
- ADMA's page on the SEC website